Valuation: Jade Biosciences, Inc.

Market Cap 1.26B 1.11B 1.02B 947M 1.8B 121B 1.82B 12.21B 4.75B 59.2B 4.75B 4.64B 205B P/E 2026 *
-8.19x
P/E 2027 * -8.27x
Enterprise Value 1.01B 885M 815M 757M 1.44B 96.42B 1.46B 9.76B 3.8B 47.33B 3.8B 3.71B 164B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day+3.40%
1 week-0.27%
Current month-0.27%
1 month+47.93%
3 months+35.45%
6 months+68.07%
Current year+43.62%
1 week 20.2
Extreme 20.2
23.12
1 month 14.28
Extreme 14.28
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer 53 22/04/2026
Director TitleAgeSince
Director/Board Member 50 28/04/2025
Director/Board Member 42 28/04/2025
Chairman 57 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/06Free

Director

47,675 0.0966%
09/06
Fairmount Funds Management LLC
FreeCompany 34,843 0.0706%
09/06Free

Chairman

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
+3.40%-0.27%+112.06% - 1.26B
-1.03%+5.24%+2.94%+9.41% 50.25B
-0.13%+1.19%+416.78%+618.09% 40.39B
+1.17%+7.47%+27.83%-4.22% 34.38B
-1.16%+7.31%+26.89%+61.33% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+1.94%+2.17% - - 16.64B
-3.01%+3.83%+72.42%+133.45% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+2.85%+7.79%+104.57%+104.57% 13.75B
Average +0.59%+2.91%+86.99%+122.25% 24.72B
Weighted average by Cap. +0.10%+4.06%+95.15%+140.32%

Financials

2026 *2027 *
Net sales - -
Net income -173M -152M -140M -130M -246M -16.52B -250M -1.67B -651M -8.11B -650M -636M -28.12B -191M -167M -154M -143M -272M -18.24B -276M -1.85B -718M -8.95B -718M -702M -31.04B
Net Debt -254M -222M -205M -190M -360M -24.18B -365M -2.45B -953M -11.87B -952M -931M -41.16B -300M -263M -242M -225M -427M -28.64B -433M -2.9B -1.13B -14.06B -1.13B -1.1B -48.75B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
08/07/26 USD 22.16 +4.04% 303,014
06/07/26 USD 21.30 -0.98% 1,056,288
02/07/26 USD 21.51 -1.38% 1,204,531
01/07/26 USD 21.81 -1.85% 861,567
30/06/26 USD 22.22 +0.50% 893,408
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.30USD
Average target price
48.50USD
Spread / Average Target
+127.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock